ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence.

Human Molecular Genetics
Orna LevranMary Jeanne Kreek

Abstract

Methadone is a mu-opioid receptor agonist used for treating opiate dependence. The range of effective methadone doses is broad. Part of the large inter-individual variability in efficacy may be accounted for by genetic factors. Methadone is a substrate of the transporter P-glycoprotein (P-gp) 170 that is encoded by the ABCB1 (MDR1) gene. Thus, P-gp variants may play a role in methadone absorption and distribution. We assessed the association between ABCB1 polymorphisms and methadone dose requirements in 98 methadone-maintained patients. The stabilizing methadone doses were normally distributed with a mean and median dose of 160 mg/day (range 30-280 mg/day). Statistical analysis showed significant difference in genotype frequencies between the 'higher' (>150 mg/day) and 'lower' (< or =150 mg/day) methadone dose groups for single nucleotide polymorphism (SNP) 1236C>T (rs1128503) (experiment-wise P = 0.0325). Furthermore, individuals bearing the 3-locus genotype pattern TT-TT-TT (rs1045642, rs2032582 and rs1128503) have an approximately 5-fold chance of requiring the 'higher' methadone dose, while individuals heterozygous for these three SNPs have an approximately 3-fold chance of stabilizing at the 'lower' methadone dose (point-w...Continue Reading

References

Jan 1, 1976·Annals of the New York Academy of Sciences·M J KreekF H Field
May 13, 1976·The New England Journal of Medicine·M J KreekL M Giusti
Jan 1, 1992·Journal of Substance Abuse Treatment·A T McLellanM Argeriou
Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A T FojoI Pastan
Mar 1, 1981·British Journal of Hospital Medicine·A J Eisinger
Mar 1, 1981·Annals of Internal Medicine·T G TongN L Benowitz
Mar 15, 2000·Proceedings of the National Academy of Sciences of the United States of America·S HoffmeyerU Brinkmann
Aug 15, 2001·Clinical Pharmacology and Therapeutics·R B KimG R Wilkinson
May 25, 2002·Science·Stacey B GabrielDavid Altshuler
Sep 11, 2002·Journal of Substance Abuse Treatment·Mary Jeanne Kreek, Frank J Vocci
Aug 2, 2003·Pharmacogenetics·Deanna L KroetzUNKNOWN Pharmacogenetics of Membrane Transporters Investigators
Oct 25, 2003·Oncogene·Suresh V AmbudkarMichael M Gottesman
Dec 31, 2003·Biochemical Pharmacology·Claude DagenaisGary M Pollack
Jan 30, 2004·Clinical Pharmacology and Therapeutics·Catia MarzoliniRichard B Kim
Feb 21, 2004·Human Molecular Genetics·Kun TangCaroline G L Lee
Jul 29, 2004·The Journal of Pharmacology and Experimental Therapeutics·Hiroshi TakaneIchiro Ieiri
Aug 7, 2004·Bioinformatics·J C BarrettM J Daly
Sep 24, 2004·Current Topics in Medicinal Chemistry·Toshiyuki SakaedaKatsuhiko Okumura
May 27, 2005·Pharmacoepidemiology and Drug Safety·Ellen C Pearson, Raymond L Woosley
Sep 6, 2005·Pharmacogenetics and Genomics·Danxin WangWolfgang Sadée
Jul 28, 2006·British Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park
Dec 21, 2006·Clinical Pharmacology and Therapeutics·Janet K CollerAndrew A Somogyi
Dec 23, 2006·Science·Chava Kimchi-SarfatyMichael M Gottesman
Dec 26, 2006·Pharmacogenomics·Chava Kimchi-SarfatyMichael M Gottesman
Mar 7, 2007·Clinical Pharmacology and Therapeutics·Andrew A SomogyiJanet K Coller
May 15, 2007·Clinical Pharmacology and Therapeutics·H GurneyH Schran

❮ Previous
Next ❯

Citations

Jun 2, 2010·The Pharmacogenomics Journal·B OnedaC B Eap
Dec 15, 2010·The New England Journal of Medicine·Hendrée E JonesGabriele Fischer
Apr 22, 2010·Journal of Addictive Diseases·Mary Jeanne KreekBrenda Ray
Jul 11, 2013·Behavioural Pharmacology·Jermaine D Jones, Sandra D Comer
Mar 22, 2012·The Journal of Pharmacology and Experimental Therapeutics·Eduardo R ButelmanThomas E Prisinzano
Oct 2, 2012·The Journal of Clinical Investigation·Mary Jeanne KreekEduardo R Butelman
Dec 12, 2012·Pharmacogenomics and Personalized Medicine·Pascal H VuilleumierRuth Landau
Apr 21, 2009·Pharmacogenomics·Grace S Y PangCaroline G L Lee
May 28, 2010·Pharmacogenomics·Ulrike M StamerFrank Stüber
Apr 6, 2013·Pharmacogenomics·Aline HajjKatell Peoc'h
Apr 1, 2014·Revista colombiana de psiquiatría·Carlos IsazaAna Sepúlveda
Apr 9, 2014·Forensic Science International : Synergy·Salumeh BastamiSrinivas Uppugunduri
Jun 24, 2014·Pharmacogenomics·Andrew A SomogyiJanet K Coller
Jul 6, 2014·Best Practice & Research. Clinical Anaesthesiology·Andrea M Trescot
Sep 12, 2014·Current Psychiatry Reports·Brian ReedMary Jeanne Kreek
May 19, 2011·Expert Opinion on Drug Metabolism & Toxicology·Paul J Jannetto, Nancy C Bratanow
Jul 16, 2010·Expert Opinion on Investigational Drugs·Marta Rodríguez-AriasJosé Miñarro
Aug 28, 2014·Expert Opinion on Drug Metabolism & Toxicology·Oliver Bruhn, Ingolf Cascorbi
Jul 16, 2009·Current Medical Research and Opinion·Neal E Slatkin
Aug 17, 2010·Forensic Science International : Synergy·Maren Kleine-BrueggeneyUlrike M Stamer
Mar 31, 2015·Drug and Alcohol Dependence·Jermaine D Jones, Sandra D Comer
Mar 6, 2010·Annals of the New York Academy of Sciences·Vadim YuferovMary Jeanne Kreek
Jan 6, 2015·British Journal of Clinical Pharmacology·Stéphane MoulyFlorence Vorspan
Jun 15, 2013·Mediators of Inflammation·Svatopluk SvětlíkOndřej Slanař
May 15, 2015·Pharmaceutical Research·Robert GharaviHazem E Hassan
Jan 24, 2012·Drug and Alcohol Dependence·David A NielsenMary Jeanne Kreek
Mar 25, 2015·Biochemical Pharmacology·Scott D CampbellEvan D Kharasch
Dec 3, 2014·Drug and Alcohol Dependence·Gavin BartRichard C Brundage
Jun 10, 2014·Clinical Biochemistry·Bhushan M KapurJulie L V Shaw
Nov 6, 2009·The International Journal of Neuropsychopharmacology·Nicolas TournierXavier Declèves

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.